Nurix Therapeutics, Inc.NRIXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel targeted protein degradation therapies for cancer, immune disorders and other serious unmet medical needs. Its core pipeline leverages proprietary E3 ubiquitin ligase modulation technology, with operations primarily based in the United States and collaborative partnerships with global pharmaceutical firms.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 10.20% | 6.0M | ▲ +0.60pp | 2024-06-07 |
| Redmile Group, LLC | 9.90% | 7.0M | flat | 2024-11-14 |
| Baker Bros. Advisors LP | 9.70% | 6.8M | ▼ -0.29pp | 2024-11-14 |
| ARK | 6.59% | 3.2M | — | 2024-01-29 |
| Deep Track Capital, LP | 6.18% | 3.0M | — | 2024-02-14 |
| Wellington Management Group LLP | 5.41% | 3.5M | — | 2024-11-08 |
| The Vanguard Group | 5.36% | 2.6M | — | 2024-02-13 |
| T. ROWE PRICE ASSOCIATES, INC. | 4.90% | 2.4M | — | 2024-02-14 |
| S/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS | 4.70% | 3.3M | ▼ -0.70pp | 2024-11-14 |
| STATE STREET CORPORATION | 1.90% | 67.1K | — | 2024-01-23 |
| Wasatch Advisors LP | 1.10% | — | ▼ -4.60pp | 2024-11-14 |
Insider Transactions
Net 90d: −$340.3K · buys $0 / sells $340.3KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-05-01 | Christine Ring | Chief Legal Officer | Sell (open market) | 5.4K | $16.76 | $90.4K |
| 2026-04-02 | Christine Ring | Chief Legal Officer | Sell (open market) | 8.1K | $15.24 | $124.1K |
| 2026-03-02 | Christine Ring | Chief Legal Officer | Sell (open market) | 8.1K | $15.44 | $125.8K |
1–3 of 3